Cargando…
Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells
Rhabdomyosarcoma (RMS) is a highly malignant and metastatic pediatric cancer arising from skeletal muscle myogenic progenitors. Recent studies have shown an important role for AKT signaling in RMS progression. Aberrant activation of the PI3K/AKT axis is one of the most frequent events occurring in h...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104989/ https://www.ncbi.nlm.nih.gov/pubmed/35566091 http://dx.doi.org/10.3390/molecules27092742 |
_version_ | 1784707929801228288 |
---|---|
author | Piazzi, Manuela Bavelloni, Alberto Cenni, Vittoria Salucci, Sara Bartoletti Stella, Anna Tomassini, Enrica Scotlandi, Katia Blalock, William L. Faenza, Irene |
author_facet | Piazzi, Manuela Bavelloni, Alberto Cenni, Vittoria Salucci, Sara Bartoletti Stella, Anna Tomassini, Enrica Scotlandi, Katia Blalock, William L. Faenza, Irene |
author_sort | Piazzi, Manuela |
collection | PubMed |
description | Rhabdomyosarcoma (RMS) is a highly malignant and metastatic pediatric cancer arising from skeletal muscle myogenic progenitors. Recent studies have shown an important role for AKT signaling in RMS progression. Aberrant activation of the PI3K/AKT axis is one of the most frequent events occurring in human cancers and serves to disconnect the control of cell growth, survival, and metabolism from exogenous growth stimuli. In the study reported here, a panel of five compounds targeting the catalytic subunits of the four class I PI3K isoforms (p110α, BYL-719 inhibitor; p110β, TGX-221 inhibitor; p110γ, CZC24832; p110δ, CAL-101 inhibitor) and the dual p110α/p110δ, AZD8835 inhibitor, were tested on the RMS cell lines RD, A204, and SJCRH30. Cytotoxicity, cell cycle, apoptosis, and the activation of downstream targets were analyzed. Of the individual inhibitors, BYL-719 demonstrated the most anti-tumorgenic properties. BYL-719 treatment resulted in G1/G0 phase cell cycle arrest and apoptosis. When combined with CAL-101, BYL-719 decreased cell viability and induced apoptosis in a synergistic manner, equaling or surpassing results achieved with AZD8835. In conclusion, our findings indicate that BYL-719, either alone or in combination with the p110δ inhibitor, CAL-101, could represent an efficient treatment for human rhabdomyosarcoma presenting with aberrant upregulation of the PI3K signaling pathway. |
format | Online Article Text |
id | pubmed-9104989 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91049892022-05-14 Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells Piazzi, Manuela Bavelloni, Alberto Cenni, Vittoria Salucci, Sara Bartoletti Stella, Anna Tomassini, Enrica Scotlandi, Katia Blalock, William L. Faenza, Irene Molecules Article Rhabdomyosarcoma (RMS) is a highly malignant and metastatic pediatric cancer arising from skeletal muscle myogenic progenitors. Recent studies have shown an important role for AKT signaling in RMS progression. Aberrant activation of the PI3K/AKT axis is one of the most frequent events occurring in human cancers and serves to disconnect the control of cell growth, survival, and metabolism from exogenous growth stimuli. In the study reported here, a panel of five compounds targeting the catalytic subunits of the four class I PI3K isoforms (p110α, BYL-719 inhibitor; p110β, TGX-221 inhibitor; p110γ, CZC24832; p110δ, CAL-101 inhibitor) and the dual p110α/p110δ, AZD8835 inhibitor, were tested on the RMS cell lines RD, A204, and SJCRH30. Cytotoxicity, cell cycle, apoptosis, and the activation of downstream targets were analyzed. Of the individual inhibitors, BYL-719 demonstrated the most anti-tumorgenic properties. BYL-719 treatment resulted in G1/G0 phase cell cycle arrest and apoptosis. When combined with CAL-101, BYL-719 decreased cell viability and induced apoptosis in a synergistic manner, equaling or surpassing results achieved with AZD8835. In conclusion, our findings indicate that BYL-719, either alone or in combination with the p110δ inhibitor, CAL-101, could represent an efficient treatment for human rhabdomyosarcoma presenting with aberrant upregulation of the PI3K signaling pathway. MDPI 2022-04-24 /pmc/articles/PMC9104989/ /pubmed/35566091 http://dx.doi.org/10.3390/molecules27092742 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Piazzi, Manuela Bavelloni, Alberto Cenni, Vittoria Salucci, Sara Bartoletti Stella, Anna Tomassini, Enrica Scotlandi, Katia Blalock, William L. Faenza, Irene Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells |
title | Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells |
title_full | Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells |
title_fullStr | Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells |
title_full_unstemmed | Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells |
title_short | Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells |
title_sort | combined treatment with pi3k inhibitors byl-719 and cal-101 is a promising antiproliferative strategy in human rhabdomyosarcoma cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104989/ https://www.ncbi.nlm.nih.gov/pubmed/35566091 http://dx.doi.org/10.3390/molecules27092742 |
work_keys_str_mv | AT piazzimanuela combinedtreatmentwithpi3kinhibitorsbyl719andcal101isapromisingantiproliferativestrategyinhumanrhabdomyosarcomacells AT bavellonialberto combinedtreatmentwithpi3kinhibitorsbyl719andcal101isapromisingantiproliferativestrategyinhumanrhabdomyosarcomacells AT cennivittoria combinedtreatmentwithpi3kinhibitorsbyl719andcal101isapromisingantiproliferativestrategyinhumanrhabdomyosarcomacells AT saluccisara combinedtreatmentwithpi3kinhibitorsbyl719andcal101isapromisingantiproliferativestrategyinhumanrhabdomyosarcomacells AT bartolettistellaanna combinedtreatmentwithpi3kinhibitorsbyl719andcal101isapromisingantiproliferativestrategyinhumanrhabdomyosarcomacells AT tomassinienrica combinedtreatmentwithpi3kinhibitorsbyl719andcal101isapromisingantiproliferativestrategyinhumanrhabdomyosarcomacells AT scotlandikatia combinedtreatmentwithpi3kinhibitorsbyl719andcal101isapromisingantiproliferativestrategyinhumanrhabdomyosarcomacells AT blalockwilliaml combinedtreatmentwithpi3kinhibitorsbyl719andcal101isapromisingantiproliferativestrategyinhumanrhabdomyosarcomacells AT faenzairene combinedtreatmentwithpi3kinhibitorsbyl719andcal101isapromisingantiproliferativestrategyinhumanrhabdomyosarcomacells |